Apogee Therapeutics, Inc.
APGE
$82.93
-$1.67-1.97%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -274.62M | -255.84M | -253.67M | -237.67M | -205.39M |
| Total Depreciation and Amortization | 1.62M | 1.42M | 1.09M | 730.00K | 367.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 49.44M | 42.45M | 36.69M | 28.21M | 20.65M |
| Change in Net Operating Assets | -10.98M | -15.48M | -16.58M | -12.02M | -3.64M |
| Cash from Operations | -234.54M | -227.45M | -232.48M | -220.74M | -188.02M |
| Capital Expenditure | -830.00K | -5.15M | -5.08M | -5.84M | -5.12M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -227.08M | -174.43M | 160.50M | -3.07M | -230.62M |
| Cash from Investing | -227.91M | -179.57M | 155.42M | -8.90M | -235.74M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 807.04M | 396.49M | 65.90M | 46.54M | 45.36M |
| Repurchase of Common Stock | -- | -- | -- | -- | -150.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 807.04M | 396.49M | 65.90M | 46.54M | 45.21M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 344.59M | -10.53M | -11.16M | -183.11M | -378.54M |